Human Insulin Market: Information by Type (Traditional Human Insulin (Premixed Traditional, Intermediate Acting and Short-Acting), Modern Human Insulin (Premixed Modern, Long-Acting and Rapid Acting) and Brand (Lantus, Novorapid, Humalog, Novomix, Levemir, Apidar, Humulin and Insuman)) - Forecast till 2030
ID: MRFR/Pharma/0445-CR | February 2021 | Region: Global | 117 Pages
1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3 Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Macroeconomic Indicators
4.5 Trends & Assessment
5 Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Opportunities
6 Human Insulin Market, by Type
6.1 Introduction
6.2 Traditional Human Insulin
6.2.1 Premixed Traditional
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.2.2 Intermediate Acting
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.2.3 Short Acting
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.3 Modern Human Insulin
6.3.1 Premixed Modern
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.3.2 Long Acting
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.3.3 Rapid Acting
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7 Human Insulin Market, by Brand
7.1 Introduction
7.2 Lantus
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.3 Novorapid
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.4 Humalog
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.5 Novomix
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.6 Levemir
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.7 Apidar
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.8 Humulin
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.9 Insuman
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
8 Global Human Insulin Market, by Region
8.1 Introduction
8.2 Americas
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.2.1 North America
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.2.1.1 US
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.2.1.2 Canada
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.2.2 South America
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.3 Europe
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.3.1 Western Europe
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.3.1.1 Germany
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.3.1.2 France
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.3.1.3 Italy
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.3.1.4 Spain
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.3.1.5 UK
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.3.1.6 Rest of Western Europe
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.3.2 Eastern Europe
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.4 Asia-Pacific
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.4.1 Japan
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.4.2 China
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.4.3 India
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.4.4 Australia
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.4.5 South Korea
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.4.6 Rest of Asia-Pacific
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.5 Middle East & Africa
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.5.1 Middle East
Human Insulin Market, by Type
Human Insulin Market, by Brand
8.5.2 Africa
Human Insulin Market, by Type
Human Insulin Market, by Brand
9 Company Landscape
9.1 Introduction
9.2 Market Share Analysis
9.3 Key Development & Strategies
10 Company Profiles
10.1 ADOCIA
10.1.1 Company Overview
10.1.2 Product Overview
10.1.3 Financials Overview
10.1.4 Key Developments
10.1.5 SWOT Analysis
10.2 MERCK & CO., INC.
10.2.1 Company Overview
10.2.2 Product Overview
10.2.3 Financial Overview
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.3 Julphar
10.3.1 Company Overview
10.3.2 Product Overview
10.3.3 Financial Overview
10.3.4 Key Development
10.3.5 SWOT Analysis
10.4 Pfizer Inc.
10.4.1 Company Overview
10.4.2 Product Overview
10.4.3 Financial Overview
10.4.4 Key Development
10.4.5 SWOT Analysis
10.5 Bristol-Myers Squibb Company
10.5.1 Company Overview
10.5.2 Product Overview
10.5.3 Financial overview
10.5.4 Key Developments
10.5.5 SWOT Analysis
10.6 GLAXOSMITHKLINE PLC
10.6.1 Company Overview
10.6.2 Product Overview
10.6.3 Financial Overview
10.6.4 Key Developments
10.6.5 SWOT Analysis
10.7 SANOFI
10.7.1 Overview
10.7.2 Product Overview
10.7.3 Financials
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.8 Oramed
10.8.1 Overview
10.8.2 Product Overview
10.8.3 Financials
10.8.4 Key Developments
10.8.5 SWOT Analysis
10.9 Novo Nordisk India Pvt. Ltd
10.9.1 Overview
10.9.2 Product Overview
10.9.3 Financials
10.9.4 Key Developments
10.9.5 SWOT Analysis
10.10 Eli Lilly and Company
10.10.1 Overview
10.10.2 Product Overview
10.10.3 Financials
10.10.4 Key Developments
10.10.5 SWOT Analysis
10.11 BIOCON
10.11.1 Overview
10.11.2 Product Overview
10.11.3 Financials
10.11.4 Key Developments
10.11.5 SWOT Analysis
10.12 Tonghua Dongbao Pharmaceutical Co., Ltd
10.12.1 Overview
10.12.2 Product Overview
10.12.3 Financials
10.12.4 Key Developments
10.12.5 SWOT Analysis
10.13 Others
11 MRFR Conclusion
11.1 Key Findings
11.1.1 From CEO’s Viewpoint
11.1.2 Unmet Needs of the Market
11.2 Key Companies to Watch
11.3 Predictions for the global Human Insulin market
12 Appendix
13 LIST OF TABLES
Table 1 Human Insulin Market Synopsis, 2020–2027
Table 2 Human Insulin Market Estimates and Forecast, 2020–2027 (USD Million)
Table 3 Global Human Insulin Market, by Region, 2020–2027 (USD Million)
Table 4 Global Human Insulin Market, by Type, 2020–2027 (USD Million)
Table 5 Global Human Insulin Market, by Brand, 2020–2027 (USD Million)
Table 6 North America: Human Insulin Market, by Type, 2020–2027 (USD Million)
Table 7 North America: Human Insulin Market, by Brand, 2020–2027 (USD Million)
Table 8 US: Human Insulin Market, by Type, 2020–2027 (USD Million)
Table 9 US: Human Insulin Market, by Brand, 2020–2027 (USD Million)
Table 10 Canada: Human Insulin Market, by Type, 2020–2027 (USD Million)
Table 11 Canada: Human Insulin Market, by Brand, 2020–2027 (USD Million)
Table 12 South America: Human Insulin Market, by Type, 2020–2027 (USD Million)
Table 13 South America: Human Insulin Market, by Brand, 2020–2027 (USD Million)
Table 14 Europe: Human Insulin Market, by Type, 2020–2027 (USD Million)
Table 15 Europe: Human Insulin Market, by Brand, 2020–2027 (USD Million)
Table 16 Western Europe: Human Insulin Market, by Type, 2020–2027 (USD Million)
Table 17 Western Europe: Human Insulin Market, by Brand, 2020–2027 (USD Million)
Table 18 Eastern Europe: Human Insulin Market, by Type, 2020–2027 (USD Million)
Table 19 Eastern Europe: Human Insulin Market, by Brand, 2020–2027 (USD Million)
Table 20 Asia-Pacific: Human Insulin Market, by Type, 2020–2027 (USD Million)
Table 21 Asia-Pacific: Human Insulin Market, by Brand, 2020–2027 (USD Million)
Table 22 Middle East & Africa: Human Insulin Market, by Type, 2020–2027 (USD Million)
Table 23 Middle East & Africa: Human Insulin Market, by Brand, 2020–2027 (USD Million)
14 LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Human Insulin Market
Figure 3 Market Dynamics for Global Human Insulin Market
Figure 4 Human Insulin Market Share, by Type, 2020
Figure 5 Human Insulin Market Share, by Brand, 2020
Figure 6 Human Insulin Market Share, by Region, 2020
Figure 7 North America: Human Insulin Market Share, by Country, 2020
Figure 8 Europe: Human Insulin Market Share, by Country, 2020
Figure 9 Asia-Pacific: Human Insulin Market Share, by Country, 2020
Figure 10 Middle East & Africa: Human Insulin Market Share, by Region, 2020
Figure 11 Human Insulin Market: Company Share Analysis, 2020 (%)
Figure 12 ADOCIA: Key Financials
Figure 13 ADOCIA: Segmental Revenue
Figure 14 ADOCIA: Geographical Revenue
Figure 15 MERCK & CO., INC.: Key Financials
Figure 16 MERCK & CO., INC.: Segmental Revenue
Figure 17 MERCK & CO., INC.: Geographical Revenue
Figure 18 Julphar: Key Financials
Figure 19 Julphar: Segmental Revenue
Figure 20 Julphar: Geographical Revenue
Figure 21 Pfizer Inc.: Key Financials
Figure 22 Pfizer Inc.: Segmental Revenue
Figure 23 Pfizer Inc.: Geographical Revenue
Figure 24 Bristol-Myers Squibb Company: Key Financials
Figure 25 Bristol-Myers Squibb Company: Segmental Revenue
Figure 26 Bristol-Myers Squibb Company: Geographical Revenue
Figure 27 GLAXOSMITHKLINE PLC: Key Financials
Figure 28 GLAXOSMITHKLINE PLC: Segmental Revenue
Figure 29 GLAXOSMITHKLINE PLC: Geographical Revenue
Figure 30 Oramed: Key Financials
Figure 31 Oramed: Segmental Revenue
Figure 32 Oramed: Geographical Revenue
Figure 33 Novo Nordisk India Pvt Ltd: Key Financials
Figure 34 Novo Nordisk India Pvt Ltd: Segmental Revenue
Figure 35 Novo Nordisk India Pvt Ltd: Geographical Revenue
Figure 36 Eli Lilly and Company: Key Financials
Figure 37 Eli Lilly and Company: Segmental Revenue
Figure 38 Eli Lilly and Company: Geographical Revenue
Figure 39 SANOFI: Key Financials
Figure 40 SANOFI: Segmental Revenue
Figure 41 SANOFI: Geographical Revenue
Figure 42 BIOCON: Key Financials
Figure 43 BIOCON: Segmental Revenue
Figure 44 BIOCON: Geographical Revenue
Figure 45 Tonghua Dongbao Pharmaceutical Co., Ltd.: Key Financials
Figure 46 Tonghua Dongbao Pharmaceutical Co., Ltd.: Segmental Revenue
Figure 47 Tonghua Dongbao Pharmaceutical Co., Ltd.: Geographical Revenue
Human Insulin Market
Global Human Insulin Market is expected to grow at CAGR of 11.91% to reach USD 156478.39 Million till 2030
$156478.39
Market Size
11.91%
CAGR
USA
Dominating Region
2022-2030
Forecast Period
Segmentation
Key Players
- Adocia
- Merck & Co.Inc
- Julphar
- Pfizer Inc.
- Bristol-Myers Squibb Company
- GlaxoSmithKline Plc
- Sanofi
Drivers
- Increasing prevalence of diabetes
- rising obesity endemic
Human Insulin Market Analysis
Market Research Future (MRFR) expects the human insulin market to attain a 11.91% CAGR between 2020 and 2030. The market size could touch USD 156478.39 Million by 2030.
Diabetes is a major lifestyle-related condition that has affected a massive population worldwide. The burden of the disorder continues to surge as the worldwide population explodes. Around 100 million people worldwide require insulin, including those that suffer from Type 1 diabetes while between 15-30% of those patients are Type 2 diabetes.
Despite insulin being the primary form of treatment for diabetes, majority of that that require insulin are still unable to afford and have easy access to it. The significant costs associated with insulin analogs remains a huge factor restraining the market growth. Moreover, patients affected by diabetes are required to regularly take insulin supplements, throughout their lifetime, putting substantial financial burden on them.
However, extensive research and development in the insulin segment has risen incredibly over the years, with researchers working on developing suitable molecules for patients' use. This could help bring down chances of side effects, and enhance their efficiency. Therefore, the surging prevalence of diabetes along with obesity across the world would augment the market demand in the next few years.
Covid 19 Analysis
Covid 19 had a profound impact on the human insulin market. Due to restrictions in travel and movement of goods, there were wide disruptions in the supply chain. Moreover, the temporary shut down of manufacturing units to curb the virus spread decreased the production rate. Thus, there was a huge shortage of human insulin worldwide for a short period. However, the human insulin market has shown rapid recovery post covid period.
Market Dynamics
Drivers
The increasing prevalence of diabetes is the key factor driving the human insulin market growth. The percentage of the population suffering from obesity & diabetes has risen significantly owing to change in lifestyle and dietary habits. This is, in turn, raising the demand for human insulin.
There has been a remarkable development in insulin production technology which is further increasing its adoption rate. Newer technologies such as recombinant DNA technology have enabled mass production of insulin to meet the huge demand. Thus, this has made insulin affordable and available to reach a wider population. The ongoing research activities are also likely to increase the market value further.
The rising disposable income of people is too a major contributor to the rising demand for insulin. Moreover, increasing awareness about the disease and easy acceptance is supporting the growth of the human insulin market.
Restraints
The high cost of insulin analogs is the major factor hindering the human insulin market growth. Additionally, the patients suffering from diabetes need to take insulin supplements regularly, forever for their lifetime which puts a financial burden on the individuals. The need for highly skilled manpower and sophisticated manufacturing infrastructure increases the manufacturing cost. Furthermore, strict regulatory requirements for insulin approval are also a potential restraining factor.
Technology Analysis
Human insulin is synthetic insulin manufactured in the industry to mimic natural insulin produced by the pancreatic cells in our body. It is used as an insulin supplement to treat diabetes. Insulin is a vital hormone in our body that helps in controlling blood sugar levels and the metabolism of carbohydrates, proteins, and fat.
Human Insulin is manufactured using recombinant DNA technology by inserting an insulin-producing gene into e-coli bacteria as the host. It is used as a subcutaneous injection in the fat layer of the skin. The final product is available in vials and can be injected through syringes, insulin pumps, insulin jets, etc.
Study Objectives
This report aims to provide a complete overview of the Human Insulin market. The specific objectives of this market report are given below:
- To provide a complete overview of the Human Insulin market.
- To analyze and forecast the Human Insulin market in terms of value and volume.
- To provide information about the impact of covid 19 on the market.
- To identify the problems and prospects of the Human Insulin market
- To give details about the technological know-how of human insulin.
- To provide complete information about the regional markets and potentially growing segments.
- To identify the key players of the human insulin industry.
Segment Analysis
Segmentation of the human insulin Market, by Type
- Traditional Human Insulin
- premixed traditional
- Intermediate-acting
- Short-acting
- Modern Human Insulin
- Premixed modern
- Long-acting
- Rapid-acting
Modern human insulin is the leading market segment. The greater advantages of modern insulin especially properties like rapid action and higher efficiency increase its market value. Modern human insulin, also known as analog insulin, has a more predictable duration of action than the traditional types.
Segmentation of the human insulin market, By Applications
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational
- Prediabetes
Type - 1 diabetes leads the market segment owing to the need for regular administration of insulin. This type of diabetes is also known as insulin-dependent diabetes. In this case, pancreatic cells produce less or no insulin which raises the need for artificial supplementation.
However, type 2- diabetes is more prevalent among the other types. A study finds that about 95 % of diabetic patients suffer from type 2 diabetes. It occurs when our body doesn't make enough insulin to fulfill the body's need or is not able to utilize Insulin properties. In this case, the patient may control blood sugar level through his diet and only requires insulin in severe cases.
Segmentation of the Human insulin market, By Brand
- Humulin
- Actrapid
- Insumoc
- Humalog
- Apidra
- Lantus
- Novomix
- Others
Among different brands, Lantus is the leading Insulin brand. It is a long-acting insulin analog and is available in more than 120 countries. However, Apidra and Levemir are the fastest-growing market segments. The Apidra is a rapidly acting analog insulin type and Levemir is a long-acting insulin analog used as base insulin. Moreover, there is stiff competition among different brands which will bring a positive effect on the market.
Regional Analysis
The different regional markets for the Human Insulin market are:
- Americas
- North America
- US
- Canada
- Mexico
- South America
- Argentina
- Brazil
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia & New Zealand
- Rest of Asia-Pacific
- Rest of the world ( RoW )
- The Middle East
Americas occupy the lead market position owing to the greater prevalence of diabetes in this region. The rising geriatric and obese population are likely to increase the demand for insulin in this region as they are the most sufferer of diabetes. Moreover, high government expenditure on healthcare infrastructure and services provides a favorable environment for market growth.
Asia-pacific is the fastest growing market segment. This region also houses nearly 60 percent of the world's diabetic population. Moreover, increasing the disposable income of people and improving healthcare infrastructure are fueling the market growth. Furthermore, Fast modernization and change in lifestyle are increasing the prevalence of diabetes in this region. Moreover, the widespread presence of pharmaceutical industries and insulin manufacturing companies will boost the market growth in this region.
Europe with a large geriatric population holds a significant share in the human insulin market. According to a report, around 60 million people in Europe suffer from diabetes. Moreover, the good presence of medical research institutes and insulin manufacturing companies makes this region a leader in the insulin trade. The Middle East and Africa segment are expected to show moderate growth over the forecast period.
Competitive Landscape
The major global companies playing a key role in the Human Insulin market are :
- Adocia
- Merck & Co.Inc
- Julphar
- Pfizer Inc.
- Bristol-Myers Squibb Company
- GlaxoSmithKline Plc
- Sanofi
- Oramed
- Novo Nordisk India Pvt. Ltd.
- Eli Lilly and Company
- Biocon
- Tonghua Dongbao Pharmaceutical Co., Ltd.
Recent Developments
February 2022
Tandem Diabetes Care’s new t:connect mobile app has gotten the FDA clearance. The app helps in controlling bolus insulin dosing, says the San Diego-based diabetes tech developer. Patients that use t:slim X2 insulin pump will have access to the app to either cancel or program bolus requests, delivering an additional dose of short- or rapid-acting insulin during mealtimes to monitor the blood sugar levels.
February 2022
Biocon has entered a partnership with Viatris (previously known as Mylan) for the development and commercialization of an extensive range of insulin and biosimilar products including human insulin, aspart; insulin glargine, bevacizumab, trastuzumab, in-licensed products adalimumab, pegfilgrastim and etanercept.
Intended Audience
This report will be beneficial for every stakeholder of the Human Insulin market such as :
- Insulin manufacturing companies
- Pharmaceutical Research and Development Institutes
- Traders and distributors
- Investors
- Diabetic patients
Report Overview
This report provides an in-depth analysis of the Human Insulin market in terms of current value and future forecast. We have also highlighted the problems and prospects of the given market. Moreover, technological analysis of the product will greatly help to get details about the know-how of the product. Furthermore, this human insulin market report contains a detailed analysis of every segment of the human insulin market for the current forecast period. Human insulin market report has also highlighted the key players and the current developments in the given market.
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | 2030: 156478.39 Million |
| CAGR | 11.91% (2020-2030) |
| Base Year | 2019 |
| Forecast Period | 2020-2030 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Modern Human Insulin and Brand |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | ADOCIA, MERCK & CO., INC., Julphar, Pfizer Inc., Bristol-Myers Squibb Company, GLAXOSMITHKLINE PLC, SANOFI, Oramed, Novo Nordisk India Pvt. Ltd, Eli Lilly and Company, BIOCON, and Tonghua Dongbao Pharmaceutical Co., Ltd. |
| Key Market Opportunities | increasing affordability of human insulin |
| Key Market Drivers |
|
Frequently Asked Questions (FAQ) :
Human Insulin Market is expected to accumulate revenues at a CAGR of 11.91% By 2030.
Human Insulin Market is driven by the large prevalence of diabetes mellitus.
The large geriatric populace affected by diabetes and diabetes management are two of the secondary drivers which can fuel the Human Insulin Market.
The Americas holds the largest share of the Human Insulin Market.
Europe holds the second-largest share of the Human Insulin Market owing to heavy funds in research of diabetes.
Oramed Pharmaceuticals, Inc., ADOCIA, Julphar, Novo Nordisk A/S, Bristol-Myers Squibb Company, Tonghua Dongbao Pharmaceuticals Co., Ltd., Biocon Ltd, Merck & Co, GlaxoSmithKline, Sanofi, and Pfizer, Inc. are major players of the Global Human Insulin Market.
